Dermatology 2013

Notes: Gupta, Madhulika A

Gupta, Aditya K

Fink, Naomi H

eng

In Vitro

2013/12/18 06:00

Skinmed. 2013 Sep-Oct;11(5):273-80.

URL: http://www.ncbi.nlm.nih.gov/pubmed/24340466

Author Address: Department of Psychiatry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada . magupta@uwo.ca

 

 

Reference Type:  Journal Article

Record Number: 4574Author: Gurvits, G. E.

Year: 2013

Title: When dermatology meets gastroenterology: a case of odynophagia

Journal: Gut

Volume: 62

Issue: 6

Pages: 851, 889

Date: Jun

Short Title: When dermatology meets gastroenterology: a case of odynophagia

Alternate Journal: Gut

ISSN: 1468-3288 (Electronic)

0017-5749 (Linking)

DOI: 10.1136/gutjnl-2012-303217

Accession Number: 22851667

Keywords: Deglutition Disorders/*complications/drug therapy

Endoscopy, Gastrointestinal

Female

Humans

Middle Aged

Peptic Ulcer/diagnosis/*etiology

Notes: Gurvits, Grigoriy E

eng

Case Reports

England

2012/08/02 06:00

Gut. 2013 Jun;62(6):851, 889. doi: 10.1136/gutjnl-2012-303217. Epub 2012 Jul 31.

URL: http://www.ncbi.nlm.nih.gov/pubmed/22851667

Author Address: Department of Gastroenterology, New York University Medical Center, 530 First Avenue, SKI-9N New York, NY 10016, USA. g_gurvits@hotmail.com

 

 

Reference Type:  Journal Article

Record Number: 4263Author: Gutfreund, K., Bienias, W., Szewczyk, A. and Kaszuba, A.

Year: 2013

Title: Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use

Journal: Postepy Dermatol Alergol

Volume: 30

Issue: 3

Pages: 165-9

Date: Jun

Short Title: Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use

Alternate Journal: Postepy dermatologii i alergologii

ISSN: 1642-395X (Print)

1642-395X (Linking)

DOI: 10.5114/pdia.2013.35619

PMCID: 3834721

Accession Number: 24278069

Abstract: Topical calcineurin inhibitors (TCI) are a relatively new class of drugs used in dermatology. There are two drug forms available – tacrolimus 0.03% or 0.1% ointment and 1.0% pimecrolimus cream. The drugs act by inhibiting synthesis of proinflammatory cytokines. The only approved indication for using TCI is treatment of atopic dermatitis. The TCI may be used as an alternative therapy to corticosteroids. Tacrolimus is used to treat moderate-to-severe atopic dermatitis, pimecrolimus – mild-to-moderate atopic dermatitis. Topical calcineurin inhibitors do not cause skin atrophy and the drug absorption through the skin is minimal. The TCI have been well-studied, their efficacy was evaluated in a number of vast, long-term studies. The anti-inflammatory potency of tacrolimus ointment is similar to a corticosteroid with moderate activity, while the latter is clearly more active than pimecrolimus cream. Topical calcineurin inhibitors significantly relieve pruritus in atopic eczema.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295